All In Biotech

Drug Trial Radar · NCT04712643

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

342

Actual

Start

Mar 12, 2021

Primary completion

Feb 1, 2029

Study completion Feb 1, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.

  • BecavizumabDrug

    Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.

  • Transarterial chemoembolization (TACE)Device

    TACE will be performed by clinical demand.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TACE Progression-Free Survival (TACE PFS) as Determined by InvestigatorTime frame: Randomization to untreatable progression or TACE failure/refractoriness or death (up to approximately 46 months)
  2. Overall Survival (OS)Time frame: Randomization to death from any cause (up to approximately 94 months)

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Anhui, China

  • Peking University First Hospital

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • Beijing You An Hospital

    Beijing, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Hunan Cancer Hospital

    Changsha, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • The First Affiliated Hospital, Chongqing Medical University

    Chongqing, China

  • Southwest Hospital , Third Military Medical University

    Chongqing, China

  • The 900th Hospital of PLA joint service support force

    Fuzhou, China

  • The First Affiliated Hospital Of Fujian Medical University

    Fuzhou, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Mengchao Hepatobiliary Hospital Of Fujian Medical University

    Fuzhou, China

  • Sun Yet-sen University Cancer Center

    Guangzhou, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Jiangsu Cancer Hospital

    Nanjing, China

  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

    Nanjing, China

  • Guangxi Cancer Hospital of Guangxi Medical University

    Nanning, China

  • The First Affiliate Hospital of Guangxi Medical University

    Nanning, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Renji Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Zhongshan Hospital Fudan Unvierstiy

    Shanghai, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Tianjin Cancer Hospital

    Tianjin, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • Xi'an Inernational Medical Center Hospital

    Xi'an, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Zhuhai People's Hospital

    Zhuhai, China

  • Aichi Cancer Center

    Aichi, Japan

  • Chiba University Hospital

    Chiba, Japan

  • Kurume University Hospital

    Fukuoka, Japan

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Yokohama City University Medical Center

    Kanagawa, Japan

  • Kanagawa Cancer Center

    Kanagawa, Japan

  • Kitasato University Hospital

    Kanagawa, Japan

  • The University of Osaka Hospital

    Osaka, Japan

  • Kindai University Hospital

    Osaka, Japan

  • Toranomon Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.